APNmAb005
Based on 1 Customer Validation
APNmAb005 is a humanized monoclonal antibody targeting Tau protein oligomers (Oligomer Tau). APNmAb005 specifically binds to synaptically enriched toxic early oligomeric tau (esoTau), neutralizing and clearing toxic tau, thereby blocking pathological tau-induced synaptic dysfunction and intercellular propagation. APNmAb005 can be used for research on Alzheimer's disease and primary tauopathies.
For research use only. We do not sell to patients.
- Purity : 97.64%
- Molecular Weight:145.92 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
MAPT
In Vitro
APNmAb005 specifically recognizes pathological early-stage oligomeric tau (esoTau) in synaptosomes and insoluble fractions from healthy and AD brain component samples, while it barely binds normal monomeric tau[2].
APNmAb005 (1:1000-1:10000 dilution; 24 h) detects early tau conformers in human AD tissue and recognizes 3R, 4R, and mixed tau aggregates in tauopathies, including glial and neuronal inclusions in PSP[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:rTg4510 transgenic (P301L human tau, male, approximately 3 months old at study start)[2]
-
Dosage:10 mg/kg or 50 mg/kg
-
Administration:i.p.; twice daily; 12 weeks
-
Result:In rTg4510 mice, partial rescue of neuronal loss was observed in the hippocampus dentate gyrus and CA1 region after twelve weeks at the high dose.
At the lower dose, neuronal loss was still reduced in the dentate gyrus.
Total tau levels in brain lysates increased with both doses.
The levels of pTau detected by AT8, synaptophysin, and esoTau also increased in the high-dose group.
Did not appear to promote overall clearance of misfolded tau aggregates.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 SH-SY5Y cells labeling Tau with APNmAb005 (HY-P991373, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa Isotype Control (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.92 kDa
-
Color Colorless to light yellow
-
SMILES
[APNmAb005]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)